Drug1-1-150 (ranked by rate) | No. of patients with reported cardiac failure during month 1 | No. of patient-months of exposure during month 1 | Rate (events per 1000 months of exposure) | Mean (SD) age | Males (%) |
---|---|---|---|---|---|
Xamoterol | 97 | 4 463 | 21.7 | 70.8 (13.9) | 53.0 |
Nicorandil | 73 | 11 578 | 6.3 | 66.9 (11.2) | 61.1 |
Bambuterol | 29 | 5 891 | 4.9 | 58.5 (18.6) | 44.8 |
Losartan | 53 | 12 990 | 4.1 | 63.5 (12.1) | 40.2 |
Diltiazem | 24 | 8 808 | 2.7 | 62.3 (13.9) | 59.3 |
Enalapril | 33 | 13 544 | 2.4 | 61.2 (14.9) | 46.1 |
Perindopril | 17 | 8 368 | 2.0 | 61.8 (12.7) | 45.0 |
Nicardipine | 17 | 9 517 | 1.8 | 62.9 (13.9) | 48.4 |
Lisinopril | 18 | 11 574 | 1.6 | 60.9 (14.3) | 44.0 |
Ramipril | 2 | 1 277 | 1.6 | 60.5 (12.4) | 45.1 |
Amlodipine | 12 | 12 085 | 1.0 | 61.8 (14.7) | 46.9 |
↵1-1-150 Betaxolol, doxazosin, isradipine not shown as number of patients with event was <2, or rate was <1.0 per 1000 patient-months of exposure.